Moreover, therapies that disrupt DNA damage repair to elevate cytosolic DNA levels, such as PARP inhibitor, CHK1 inhibitor, and ATM inhibitor, synergize with anti-tumor immunotherapy in part through activating the cGAS/STING pathway15–17. This evidence concerns the gene STING1 and neoplasm.